Patients with diabetes mellitus are at increased risk of developing atherosclerotic disease. The extent of this additional risk and its determinants are not well known, but this information is needed for sample-size estimations in intervention studies. Therefore, a meta-analysis of epidemiologic studies on this subject was performed. Medline was searched from 1966 onwards, including the reference lists of all relevant publications. A total of 27 prospective follow-up studies in the English language that allowed calculation of the unadjusted incidence of one of the predefined outcome events were included. The influence of age, sex, type of diabetes, duration of diabetes, year of study, HbA 1c , cholesterol level, blood pressure and smoking on these incidences was studied by means of univariate Poisson regression analysis.
Introduction
Macrovascular disease is the cause of increased morbidity and premature death in patients with diabetes mellitus. 1, 2 Ischaemic heart disease and cerebrovascular disease are manifestations of macroangiopathy. Interventions that may prevent macrovascular complications of diabetes mellitus are of current interest. 3, 4 The incidence of cardiovascular events in subjects without diabetes can be reduced by lowering cholesterol or blood pressure. 5, 6 The sample size of randomized clinical trials on the effects of cardiovascular risk factor interventions on the incidence of macrovascular disease in a diabetic population depends on the expected incidence of cardiovascular events. However, data from the literature on mortality and the incidence of macrovascular disease in diabetes vary greatly. Moreover, there is a lack of reliable data on the overall burden of macrovascular disease as expressed in a comprehensive outcome event.
To obtain a reliable estimate of the mortality and the incidence of cardiovascular events in patients with diabetes mellitus, a meta-analysis of all epidemiological studies on this subject performed in the last three decades was conduc-ted. Furthermore, which variables influence this incidence were analysed.
Methods
To identify studies on mortality and the incidence of cardiovascular events in diabetes mellitus, a Medline literature search from January 1966 until January 1997 was performed, including a search of the reference lists of all relevant publications for other incidence studies. Inclusion criteria for the meta-analysis are given in Table 1 . Only prospective Table 1 Inclusion criteria for the studies used in the metaanalysis.
ț Unadjusted incidence figures are given for at least one of the following outcome measurements:
-total mortality -death from all vascular causes -death from all vascular causes, non-fatal myocardial infarction, or non-fatal stroke -death from all vascular causes or non-fatal myocardial infarction -death from all vascular causes or non-fatal stroke -fatal or non-fatal myocardial infarction ț Prospective follow-up study ț No selection of the study population at baseline for the presence of cardiovascular disease ț Published in English studies we included in order to obtain reliable incidence estimates. Studies that included patients with cardiovascular disease at baseline were not used in order to avoid high incidence rates due to this disease. In case of multiple publications on the same population, the most recent publication was used. Studies that included only children and clinical trials were excluded because these often represent a selected group of patients. For each of the selected studies the overall incidence of the reported outcome measurement(s) was verified or computed if necessary. In addition, the following characteristics were abstracted (if reported): year of study (the mid-year of the study period was taken), mean age of the study population, percentage of women, percentage of type 1 diabetes patients, mean total cholesterol, mean systolic blood pressure, mean diastolic blood pressure, mean HbA 1c (glycated haemoglobin), mean duration of diagnosed diabetes mellitus, percentage of current smokers, percentage of patients with a history of myocardial infarction and percentage of subjects with a history of stroke.
Total mortality and death from all vascular causes are graphically presented (see Figures 1 and 2) , with an overall incidence; in addition, age-adjusted (standardized age 60 years) mortality is displayed. The calculation of 95% confidence intervals for the incidences was based on the Poisson distribution. 7 Using Poisson regression analysis, which of the abstracted characteristics were related to the incidence of the six predefined outcome measures was investigated. Only those characteristics reported in at least eight studies were included. The influence of a characteristic on incidence is reported as a rate ratio with an accompanying 95% confidence interval, both unadjusted and adjusted for age.
Results
A total of 75 studies fulfilling the search strategy were identified, of which 27 were included. Excluded were: 14 studies because they did not report on one of the predefined outcome measurements; 14 because there was a more recent publication on the same population; seven because they reported only age-adjusted data; four because they were clinical trials; four because the patients were selected for the presence of cardiovascular disease; three because the number of patient years was not clear; one because only children were included; and one because it was retrospective. Characteristics of the included studies are summarized in Table 2 . All studies described total mortality, 16 'death from all vascular causes', 8, 9, 12, 15, 16, 18, 20, 21, [23] [24] [25] 27, 28, 31, 33, 34 only two the composite outcome event 'death from all vascular causes, non-fatal myocardial infarction or non-fatal stroke', 21, 28 three 'death from all vascular causes or nonfatal myocardial infarction', 20, 21, 28 two 'death from all vascular causes or non-fatal stroke' 21,28 and three 'fatal or nonfatal myocardial infarction'. 20, 21, 28 Total mortality figures are given in Figure 1a , while ageadjusted mortality data are depicted in Figure 1b per year in a Finnish cohort, with a relatively high mean cholesterol level. 28 The incidences of the other outcome measurements are depicted in Table 3 . The Nurses' Health Study cohort consisted of relatively young and healthy women, which may explain the low incidences in this study. 21 The overall yearly total mortality was 2.9% (95% CI 2.8-3.0; 27 studies) and death from all vascular causes was 1.4% (95% CI 1.3-1.4; 16 studies). Total yearly mortality in the 16 studies that reported on death from all vascular causes was 2.7% (95% CI 2.7-2.8). When the Nurses' Health Study was excluded from the analysis, the overall yearly total mortality and death from all vascular causes were 3.0% (95% CI 3.0-3.1; 26 studies) and 1.5% (95% CI 1.4-1.5; 15 studies), respectively. In the 11 studies performed in patients with type 2 diabetes only, these figures were 3.8% (95% CI 3.6-4.0) and 2.7% (95% CI 2.4-3.0), respectively.
Results of the Poisson regression analysis are shown in Table 4 . Only total mortality and death from all vascular causes were used as outcome measures because not enough studies reported on the four other outcome measures. Only studies that provided data on mean age were included in this analysis in order to be able to compare crude and ageadjusted rate ratios. Crude rate ratios and confidence intervals for all studies were essentially similar to those for the studies that provided data on mean age. Adjusted for age, both total mortality and death from all vascular causes increased significantly with a more recent year of study, the total cholesterol level and systolic blood pressure, and decreased with the percentage of women ( Table 3 ). The percentage of patients with diabetes type 1 and the percentage of current smokers were only related to total mortality. In studies restricted to type 2 diabetes patients, the ageadjusted rate ratios for total mortality were: mid-year of study 1.015 (95% CI 0.992-1.039; n = 11), percentage of women 0.987 (95% CI 0.977-0.997; n = 11) and mean duration of diabetes 1.028 (95% CI 1.006-1.050; n = 9). The other characteristics, as well as death from all vascular causes, were only reported in five studies. When the first year of the study period was taken instead of the mid-year the rate ratios were essentially the same. In multivariate analyses it was attempted to identify all independent characteristics related to mortality. However, due to the lack of data only 10 studies could be identified that simultaneously reported information on four characteristics. Multivariate analysis of this restricted data set yielded no results that had not been presented in Table 4 .
The authors also analysed whether total mortality increased within study populations with a more recent year of study. Data that could be used for this purpose were published in three of the included studies. 14, 24, 25 The yearly incidence for the study from Osaka was 2.2% (95% CI 1.9-2.5) in 1972 35 and 2.8% (95% CI 2.5-3.0) in 1975, 14 for the WHO Multinational Study it was 1.8% (95% CI 1.6-1.9) in 1979 36 and 2.5% (95% CI 2.4-2.7) in 1982, 24 and for the study from Kuopio it was 1.2% (95% CI 0.6-2.5) in 1982 37 and 3.1% (95% CI 2.3-4.3) in 1985. 25 After adjustment for age, the yearly mortality for the earlier studies was still lower than for the more recent studies: Osaka 2.6% and 2.8%, WHO 2.1% and 2.5%, and Kuopio 1.5% and 3.1%.
From the data of the meta-analysis, the incidences of total mortality (1) and death from all vascular causes (2) in a cohort with known mean age and percentage of women can be estimated using the following formulas:
In both formulas, a = mean age of the study population and b = percentage of women.
Discussion
It was found that total mortality in diabetes mellitus was 2.9% per year (95% CI 2.8-3.0), and that death from all vascular causes was 1.4% per year (95% CI 1.3-1.4). In studies limited to type 2 diabetes patients, these incidences were 3.8% and 2.7%, respectively. Adjustments for age, year of study, total cholesterol, systolic blood pressure and male gender were positively related to total mortality and death from all vascular causes. For total mortality, both the percentage of current smokers and the percentage of type Vascular Medicine 1999; 4: 67-75 1 diabetes patients were positively related. For death from all vascular causes not enough studies reported on smoking and the type of diabetes to allow conclusions. The primary composite outcome event in a clinical trial on atherosclerosis may be the overall burden of macrovascular disease, expressed by death from all vascular causes, non-fatal myocardial infarction, or non-fatal stroke. The sample size of such a clinical intervention study highly depends on the estimated incidence of this composite cardiovascular outcome event. Only two prospective followup studies were found with data about the incidence of this composite outcome measure in diabetes mellitus. 21, 28 Further data may be extrapolated from studies on subjects without diabetes mellitus. In the control groups of some large clinical trials the mean ratio between death from all vascular causes and non-fatal myocardial infarction and non-fatal stroke was 1.00:0.95:0.48. [38] [39] [40] [41] These large studies reporting the outcome measurements of interest to this paper were selected from the Antiplatelet Trialists' Collaboration paper 42 and concern patients with intermittent claudication and subjects without vascular disease at base- line. With an incidence of 1.4% per year for death from all vascular causes, the incidence of the composite outcome event death from all vascular causes, non-fatal myocardial infarction, or non-fatal stroke may be estimated to be approximately 3.4% per year. However, myocardial infarction has a higher case fatality in diabetic patients than in patients without diabetes. 43, 44 Therefore, the ratio between death from all vascular causes and non-fatal myocardial infarction and non-fatal stroke may be different in diabetic patients compared with non-diabetic subjects.
It was surprising to find an increase of total mortality and death from all vascular causes by year of study. This increase may be partly explained by changing the diagnostic criteria of diabetes during the last decades. Patients with diabetes mellitus in early studies might nowadays be labelled as having impaired glucose tolerance. 45 The risk of cardiovascular disease is lower for patients with impaired glucose tolerance than for those with diabetes mellitus, which may explain the better prognosis in early studies. 46 Furthermore, the increase may be explained by the improved treatment of diabetes with less microvascular complications and a better initial survival, but eventually more macrovascular disease. This hypothesis is supported by the finding of an increased mortality with time within a study.
There is no indication that the qualitative relationship of risk factors for the development of cardiovascular disease is different between patients with diabetes and the general population. 47 Our data concerning the prognostic value of Vascular Medicine 1999; 4: 67-75 age, elevated cholesterol, raised systolic blood pressure, male gender and smoking correspond with the well-known risk determinants in subjects without diabetes.
It was found that total cholesterol is a pronounced determinant of total mortality and death from all vascular causes in diabetes mellitus. This was also the strongest risk factor for the incidence of coronary artery disease during 10 years of follow-up in the large United Kingdom Prospective Diabetes Study (UKPDS). 48 Because this is not a follow-up study the results were not included in the meta-analysis. Moreover, the importance of cholesterol is confirmed by the recent subgroup analyses of two secondary prevention trails: the Scandinavian Simvastatin Survival Study (4S) and the Cholesterol and Recurrent Events trial (CARE). 49, 50 These analyses indicate that the risk reduction by cholesterol lowering in type 2 diabetes patients may be even greater than in patients without diabetes. A number of secondary prevention trials in diabetic patients is currently underway. Also, systolic blood pressure influenced total mortality and death from all vascular causes in subjects with diabetes, which is in accordance with the results of the hypertension study within the UKPDS. This study showed that tight blood pressure control (Ͻ150/85 mmHg) in patients with newly diagnosed type 2 diabetes was associated with ෂ20% reduction of cardiovascular events compared with less tight control. 51 Duration of diabetes and mean HbA 1c were not associated with mortality (Table 4 ). This is in accordance with the results of the UKPDS, which show that intensive blood reported on all the main cardiovascular outcome events. Also, the main characteristics of the patients were often not mentioned completely. As a result, a reliable estimate of the incidence of cardiovascular disease in diabetes patients is not known. Follow-up studies on the incidence of the composite outcome event death from all vascular causes, non-fatal myocardial infarction, or non-fatal stroke in welldefined cohorts of patients with type 1 and type 2 patients are needed. For each unit increase of the predictor variable the rate ratio reflects the factor by which the incidence is multiplied.
